Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — A team of clinicians is devoted to refining the classification of meibomian gland ...

Please provide your email address to receive an email when new articles are posted on . Two new treatment options are helping clinicians experience better outcomes when dealing with meibomian gland ...

The National Eye Institute, part of the National Institutes of Health, awarded Jason J. Nichols, OD, MPH, PhD, FAAO, a five-year, $1.9 million R01 grant to study potential molecular markers in ...

Dry eye disease is a condition that afflicts millions of people worldwide, causing constant discomfort and affecting their quality of life. One of the key culprits behind this condition is meibomian ...

Meibomian gland dysfunction (MGD) is the major cause of evaporative dry eye disease (EDED) and dysfunction is widely thought to mechanistically involve ductal hyperkeratinization, plugging and ...

Twenty eyes of 20 vitiligo patients (Group 1) and 20 eyes of 20 healthy individuals (Group 2) were enrolled. All subjects had undergone a comprehensive ophthalmic examination including corneal and ...

"DelveInsight’s, “Meibomian Gland Dysfunction- Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Meibomian Gland Dysfunction pipeline landscape ...

Meibomian gland dysfunction (MGD) is underdiagnosed and undertreated, with asymptomatic disease far more common than symptomatic disease. As the condition progresses, patients who were initially ...

TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye ...

Ocular GvHD following allogeneic stem cell transplantation (aSCT) includes inflammation of the entire lacrimal functional unit and leads to severe damage to the ocular surface. Several forms of ocular ...

TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular ...

In this review we have critically evaluated the proposed pathogenetic mechanism for MGD involving hyperkeratinization of the meibomian gland duct leading to obstruction, cystic dilation and "disuse" ...